Insight Wealth Strategies LLC Acquires 4,035 Shares of Merck & Co., Inc. $MRK

Posted by George Bondi on Aug 12th, 2026

Insight Wealth Strategies LLC grew its holdings in Merck & Co., Inc. (NYSE:MRK – Free Report) by 8.0% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 54,323 shares of the company’s stock after purchasing an additional 4,035 shares during the quarter. Insight Wealth Strategies LLC’s holdings in Merck & Co., Inc. were worth $6,810,000 as of its most recent filing with the SEC.

Several other large investors also recently made changes to their positions in MRK. Kingdom Financial Group LLC. bought a new position in shares of Merck & Co., Inc. in the fourth quarter valued at about $25,000. Prosperity Bancshares Inc bought a new stake in Merck & Co., Inc. during the 4th quarter worth about $26,000. Abound Financial LLC bought a new stake in Merck & Co., Inc. during the 4th quarter worth about $26,000. IFC & Insurance Marketing Inc. acquired a new stake in Merck & Co., Inc. in the 4th quarter valued at about $31,000. Finally, High Note Wealth LLC increased its position in Merck & Co., Inc. by 58.9% in the 4th quarter. High Note Wealth LLC now owns 294 shares of the company’s stock valued at $31,000 after acquiring an additional 109 shares in the last quarter. Institutional investors own 76.07% of the company’s stock.

Trending Headlines about Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

Positive Sentiment: The FDA and European Medicines Agency accepted supplemental applications to expand ENFLONSIA, Merck’s RSV preventive therapy, to additional high-risk young children. The potential broader indication could expand Merck’s infectious-disease portfolio and help diversify revenue beyond oncology. Merck Wins FDA and EMA Review for Broader RSV Use in Children
Positive Sentiment: Argus raised its price target on MRK from $130 to $145 and reiterated a “buy” rating, adding to a generally favorable analyst view. Recent targets from other firms have also reached the $146–$150 range, reflecting confidence in Keytruda, animal health and the development pipeline.
Positive Sentiment: Merck’s latest quarterly results exceeded expectations, with revenue of $16.61 billion versus a $16.37 billion consensus estimate and revenue growth of 5.1% year over year. Oncology and animal health were key contributors, while the company maintained 2026 adjusted EPS guidance of $2.66–$2.76. Merck Q2 2026 Earnings Call Transcript
Neutral Sentiment: Merck declared a quarterly dividend of $0.85, equivalent to $3.40 annually and a yield of roughly 2.6%. The dividend supports the stock’s income appeal, although the reported payout ratio is elevated because current earnings are depressed by unusual factors.
Neutral Sentiment: Reports discussing a proposal to separate the measles, mumps and rubella vaccine into three shots could create uncertainty around Merck’s vaccine business, including MMR II. Experts say the plan lacks scientific support and is unlikely to proceed. Trump Wants to Split the MMR Vaccine
Negative Sentiment: Analysts continue to flag falling estimates and the risk from upcoming Keytruda patent expirations, which could pressure Merck’s near-term growth and valuation despite strong current sales and pipeline progress. MRK Stock Up 5.6% in a Month as Estimates Fall
Negative Sentiment: Executive Vice President Richard Deluca sold 6,050 shares worth approximately $788,799. The sale reduced his holdings by 3.75%, though he continues to own a substantial position and the transaction alone is not necessarily a signal of deteriorating fundamentals. Merck EVP Sells Stock

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on the stock. CICC Research assumed coverage on shares of Merck & Co., Inc. in a research report on Wednesday, June 24th. They set an “outperform” rating and a $138.00 target price on the stock. Royal Bank Of Canada reissued an “outperform” rating and issued a $142.00 price target on shares of Merck & Co., Inc. in a report on Wednesday, July 8th. Weiss Ratings cut shares of Merck & Co., Inc. from a “hold (c+)” rating to a “hold (c)” rating in a research report on Friday, May 15th. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $120.00 price objective on shares of Merck & Co., Inc. in a report on Monday, July 6th. Finally, Barclays upped their price objective on Merck & Co., Inc. from $140.00 to $150.00 and gave the stock an “overweight” rating in a report on Wednesday, July 29th. Fourteen analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company’s stock. According to data from MarketBeat, Merck & Co., Inc. has a consensus rating of “Moderate Buy” and an average price target of $135.11.

Read Our Latest Report on Merck & Co., Inc.

Merck & Co., Inc. Stock Performance

Shares of NYSE:MRK opened at $130.35 on Wednesday. The stock has a market capitalization of $321.59 billion, a P/E ratio of 104.28, a P/E/G ratio of 5.66 and a beta of 0.19. Merck & Co., Inc. has a 1-year low of $77.58 and a 1-year high of $135.05. The company has a current ratio of 1.30, a quick ratio of 1.06 and a debt-to-equity ratio of 1.02. The business has a 50-day moving average price of $124.58 and a two-hundred day moving average price of $119.47.

Merck & Co., Inc. (NYSE:MRK – Get Free Report) last released its earnings results on Tuesday, August 4th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.13. The company had revenue of $16.61 billion for the quarter, compared to the consensus estimate of $16.37 billion. Merck & Co., Inc. had a net margin of 4.77% and a return on equity of 16.05%. The company’s revenue was up 5.1% compared to the same quarter last year. During the same period in the prior year, the company posted $2.13 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. Equities analysts predict that Merck & Co., Inc. will post 2.76 earnings per share for the current year.

Merck & Co., Inc. Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 7th. Investors of record on Tuesday, September 15th will be issued a $0.85 dividend. This represents a $3.40 annualized dividend and a yield of 2.6%. The ex-dividend date is Tuesday, September 15th. Merck & Co., Inc.’s dividend payout ratio is currently 272.00%.

Insider Buying and Selling at Merck & Co., Inc.

In other Merck & Co., Inc. news, EVP Chirfi Guindo sold 15,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 6th. The shares were sold at an average price of $131.00, for a total value of $1,965,000.00. Following the transaction, the executive vice president directly owned 46,613 shares of the company’s stock, valued at approximately $6,106,303. This trade represents a 24.35% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Richard R. Deluca sold 6,050 shares of Merck & Co., Inc. stock in a transaction on Thursday, August 6th. The stock was sold at an average price of $130.38, for a total transaction of $788,799.00. Following the sale, the executive vice president directly owned 155,487 shares of the company’s stock, valued at $20,272,395.06. This represents a 3.75% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 92,603 shares of company stock valued at $11,966,744. 0.17% of the stock is currently owned by corporate insiders.

About Merck & Co., Inc.

(Free Report)

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.